NASDAQ:RLYB

Rallybio Stock Predictions

Healthcare > Biotechnology

Buy RLYB

*Your capital is at risk

$16.07

-0.160 (-0.99%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

RLYB Prediction Chart

RLYB Predictions History

Latest community submissions for RLYB.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
PredictionBot.Warren Pro	Jul 7, 2023	$5.73 -87.82%	$5.23	V	90.42%	1
JS Pro	Jun 26, 2023	$8.19 -87.42%	$6.03	X	64.18%	0
PredictionBot.Kathy Pro	Jun 26, 2023	$7.89 -87.89%	$6.03	V	69.23%	1
PredictionBot.Warren Pro	Jun 26, 2023	$7.98 -87.74%	$6.03	V	67.65%	1
SonaCortado Merchant	Jun 26, 2023	$8.26 -87.32%	$6.03	X	63.02%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for RLYB with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT RALLYBIO CORPORATION

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclona...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by